We are analyzing https://link.springer.com/article/10.1186/ar994.

Title:
Current and new antitumor necrosis factor agents in perspective | Arthritis Research & Therapy
Description:
No description found...
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Education
Health & Fitness
Science

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 7,642,828 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We don't see any clear sign of profit-making.

Websites don't always need to be profitable; some serve as platforms for education or personal expression. Websites can serve multiple purposes. And this might be one of them. Link.springer.com might be making money, but it's not detectable how they're doing it.

Keywords {🔍}

arthritis, article, google, scholar, rheumatoid, agents, pubmed, antitnf, infliximab, tnf, cas, maini, patients, research, clinical, data, necrosis, factor, rheumatology, administration, feldmann, privacy, cookies, information, therapy, centocor, mgkg, week, etanercept, publish, search, published, tumor, disease, response, fda, abbott, safety, content, journal, perspective, june, download, ravinder, synovial, role, cytokine, trials, elliott, usa,

Topics {✒️}

disease-modifying antirheumatic drugs randomised double-blind comparison serum c-reactive protein existing disease-modifying agents multi-centre randomized trial org/publications/hotline/0901tnf anti-tnf alpha therapy tender/swollen joint scores monoclonal anti-tnf antibody tumor necrosis factor privacy choices/manage cookies poignant research findings open-label infliximab article number s1 soluble protein etanercept approved adalimumab chimeric monoclonal antibody world class debate chimeric monoclonal antibodies significant clinical improvements swollen joint count low-dose group european economic area induces cellular recruitment human autoimmune disease ritchie articular index mann–whitney test primary end point erythrocyte sedimentation rate serum half-lives physicians' desk reference® ann intern med aud=mem] scallon pharmacol exp ther anti-tnf antibodies anti-tnf agent anti-tnf agents conditions privacy policy specifically target tnf annu rev immunol infliximab 10 mg/kg infliximab 5 mg/kg high-dose group potent proinflammatory mediator adverse event profile o'dell jr received institutional grants author information authors article maini accepting optional cookies

Questions {❓}

Brennan FM, Maini RN, Feldmann M: TNF alpha – a pivotal role in rheumatoid arthritis?
Feldmann M, Maini RN: Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned?
Maini RN, Feldmann M: How does infliximab work in rheumatoid arthritis?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Current and new antitumor necrosis factor agents in perspective
         description:
         datePublished:2004-06-21T00:00:00Z
         dateModified:2004-06-21T00:00:00Z
         pageStart:1
         pageEnd:2
         sameAs:https://doi.org/10.1186/ar994
         keywords:
            Rheumatoid Arthritis
            Infliximab
            Etanercept
            Adalimumab
            Active Rheumatoid Arthritis
            Rheumatology
            Orthopedics
         image:
         isPartOf:
            name:Arthritis Research & Therapy
            issn:
               1478-6354
            volumeNumber:6
            type:
               Periodical
               PublicationVolume
         publisher:
            name:BioMed Central
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Ravinder N Maini
               affiliation:
                     name:Imperial College of Science, Technology and Medicine
                     address:
                        name:Kennedy Institute of Rheumatology, Imperial College of Science, Technology and Medicine, London, UK
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:1
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Current and new antitumor necrosis factor agents in perspective
      description:
      datePublished:2004-06-21T00:00:00Z
      dateModified:2004-06-21T00:00:00Z
      pageStart:1
      pageEnd:2
      sameAs:https://doi.org/10.1186/ar994
      keywords:
         Rheumatoid Arthritis
         Infliximab
         Etanercept
         Adalimumab
         Active Rheumatoid Arthritis
         Rheumatology
         Orthopedics
      image:
      isPartOf:
         name:Arthritis Research & Therapy
         issn:
            1478-6354
         volumeNumber:6
         type:
            Periodical
            PublicationVolume
      publisher:
         name:BioMed Central
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Ravinder N Maini
            affiliation:
                  name:Imperial College of Science, Technology and Medicine
                  address:
                     name:Kennedy Institute of Rheumatology, Imperial College of Science, Technology and Medicine, London, UK
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:1
["Periodical","PublicationVolume"]:
      name:Arthritis Research & Therapy
      issn:
         1478-6354
      volumeNumber:6
Organization:
      name:BioMed Central
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Imperial College of Science, Technology and Medicine
      address:
         name:Kennedy Institute of Rheumatology, Imperial College of Science, Technology and Medicine, London, UK
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Ravinder N Maini
      affiliation:
            name:Imperial College of Science, Technology and Medicine
            address:
               name:Kennedy Institute of Rheumatology, Imperial College of Science, Technology and Medicine, London, UK
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Kennedy Institute of Rheumatology, Imperial College of Science, Technology and Medicine, London, UK

External Links {🔗}(66)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

3.94s.

LINK . SPRINGER . COM {}